Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: To be considered for enrollment, subjects must:~* have been randomized in protocol 012-VWAV06;~* have signed and dated an IRB-approved written informed consent to participate in 012-VWAV06 as well as this study;~* be willing to comply with all aspects of the evaluation schedule over a period of 60 months post device insertion;~* allow representatives of the sponsor, designated Clinical Research Organization (CRO), Institutional Review Board (IRB), the Ethics Committee, and U.S. Food and Drug Administration (FDA) to review his/her relevant medical records.~Exclusion Criteria:~* Subjects who withdrew or were withdrawn from study 012-VWAV06.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Graft, Vascular Wrap (Type: ACTIVE_COMPARATOR): Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
- Graft (Type: PLACEBO_COMPARATOR): Lifespan® ePTFE Vascular Graft Only

Based on this trial design, predict the completion outcome and termination type (if applicable).